Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer

CMS has determined there are no nationally covered indications for PET with F-18 sodium fluoride (NaF-18) and designates PET NaF-18 as nationally non-covered effective December 15, 2017. Other PET radiopharmaceutical tracers for cancer may be covered at local Medicare Administrative Contractor discretion when used according to their FDA‑approved indications.

"PET using F-18 sodium fluoride (NaF-18) to identify bone metastasis of cancer is nationally non-covered effective December 15, 2017."

Sign up to see full coverage criteria, indications, and limitations.